Liebson I, Bigelow G, Griffiths R R, Funderburk F R
Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland.
J Clin Pharmacol. 1987 Sep;27(9):685-93. doi: 10.1002/j.1552-4604.1987.tb03089.x.
Two controlled clinical studies evaluated the effects of phenylpropanolamine HCL (PPA) on measures of blood pressure, pulse, and subjective state (mood). One hundred fifty subjects participated in a parallel groups design that compared a 75-mg sustained release (SR) preparation with a 25-mg tid. dosing regimen and placebo. Fifty-nine of these subjects participated in an additional cross-over component that compared SR PPA 75 mg with placebo. Measures of blood pressure, pulse, and subjective drug effect were obtained nine times throughout the course of a 12-hour session. Data analysis revealed no clinically and few statistically significant effects due to drug treatment. As expected, most measures showed circadian changes on both the cardiovascular and mood variables, which were not related to drug treatment. No euphorogenic or "amphetamine-like" effects were noted. Although further work is warranted regarding the effects of chronic or higher-than-normal doses of PPA, the current studies suggest that PPA, at currently recommended dose levels, is not associated with adverse effects on either cardiovascular or subjective functioning.
两项对照临床研究评估了盐酸苯丙醇胺（PPA）对血压、脉搏和主观状态（情绪）指标的影响。150名受试者参与了一项平行组设计，该设计比较了75毫克缓释（SR）制剂与25毫克每日三次给药方案及安慰剂。其中59名受试者参与了一项额外的交叉部分，比较了75毫克SR PPA与安慰剂。在12小时的过程中，共九次测量血压、脉搏和主观药物效应。数据分析显示，药物治疗没有临床显著效果，在统计学上也仅有少量显著效果。正如预期的那样，大多数指标在心血管和情绪变量上都显示出昼夜变化，这与药物治疗无关。未观察到欣快或“类似苯丙胺”的效应。尽管对于慢性或高于正常剂量的PPA的影响仍需进一步研究，但目前的研究表明，按照目前推荐的剂量水平，PPA对心血管或主观功能均无不良影响。
